Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology

A compound of formula (1) or formula (2)

• wherein:
• X and Y are N;
• Ar is:
• phenyl optionally substituted with one or more substituents selected from the group consisting of:
• halogen, (C1–C4)alkyl, (C1–C4)alkoxy, thio(C1–C4)alkyl, NO2, NH(C1–C4)alkyl and N((C1–C4)alkyl)2 wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N,
• Z is H, 4-aminophenyl, SO2R3 or COR3 wherein R3 is (C1–C4)alkyl, (C3–C6)cycloalkyl, Ar as defined above, (C2–C6)alkenyl or (C2–C6)alkynyl;
• R1 is H, (C1–C4)alkyl, (C3–C6)cycloalkyl or Ar as defined above;
• R′ is H or (C1–C4)alkyl;
• and
• when Z is H, R2 is selected from the group consisting of:
• cyano,
• C(O)—ORa1 wherein Ra1 is methyl, ethyl or isopropyl,
• C(O)—NHRa2 wherein Ra2 is cyclopropyl,
• C(O)—N(Ra2′), wherein N(Ra2′) is aziridinyl or azetidinyl, optionally substituted with (C1–C4)alkyl or Ar as defined above,
• C(O)—N(Ra3)—ORa3 wherein each Ra3 may be identical or different and each Ra3 is independently selected from the group consisting of methyl, ethyl or cyclopropyl,
• C(O)Ra4 wherein Ra4 is Ar as defined above or (C3–C5)cycloalkyl optionally substituted with (C1–C4)alkyl or Ar as defined above,
• C(Ra4)═N—Rb wherein:
• Ra4 is H, Ar as defined above, or (C3–C5)cycloalkyl optionally substituted with (C1–C4)alkyl or Ar as defined above, and Rb is (C1–C2)alkyl, (C3–C5)cycloalkyl, hydroxyl, (C1–C4)alkoxy, (C2–C4)alkenyloxy, or (C1–C4)alkylenoxy wherein said (C1–C4)alkylenoxy optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, (CH2)nAr wherein n is 0 or 1 and Ar is as defined above, (C1–C4)alkoxy, NH2, NH(C1–C4)alkyl, and N((C1–C4alkyl)2 wherein said alkyls together with the heteroatom to which they are attached may optionally form a 3 to 6 membered ring which may optionally contain a second hetero atom selected from the group consisting of O, S and N,
• NH—C(O)Ra4 wherein Ra4 is H, Ar as defined above, or (C3–C5)cycloalkyl optionally substituted with (C1–C4)alkyl or Ar as defined above,
• NHRa4 wherein Ra4 is H, Ar as defined above, or (C3–C5)cycloalkyl optionally substituted with (C1–C4)alkyl or Ar as defined above,
• phenyl, and
• 5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms selected from the group consisting of O, N and S;
• and
• when Z is SO2R3 or COR3, R2 is carboxyl, NH2, NR(C1–C4)alkyl, N((C1–C4)alkyl)2 or (C3–C5)cycloalkylamino;
• or
• a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures of the stereoisomeric forms thereof in any ratio;
• or
• a pharmaceutically acceptable salt of the compound of formula (1) or formula (2).